ULTRAVIST 240 Drug Patent Profile

When do Ultravist 240 patents expire, and what generic alternatives are available?

Ultravist 240 is a drug marketed by Bayer Hlthcare and is included in one NDA.

The generic ingredient in ULTRAVIST 240 is iopromide. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the iopromide profile page.

Summary for ULTRAVIST 240

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	11
Patent Applications:	3,385
DailyMed Link:	ULTRAVIST 240 at DailyMed

Recent Clinical Trials for ULTRAVIST 240

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Guerbet/Liebel-Flarsheim	Phase 4
Duke Clinical Research Institute	Phase 4
GE Healthcare	Phase 4

See all ULTRAVIST 240 clinical trials

Pharmacology for ULTRAVIST 240

Drug Class	Radiographic Contrast Agent
Mechanism of Action	X-Ray Contrast Activity

US Patents and Regulatory Information for ULTRAVIST 240

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	ULTRAVIST 240	iopromide	INJECTABLE;INJECTION	020220-003	May 10, 1995		DISCN	Yes	No

Expired US Patents for ULTRAVIST 240

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	ULTRAVIST 240	iopromide	INJECTABLE;INJECTION	020220-003	May 10, 1995

International Patents for ULTRAVIST 240

See the table below for patents covering ULTRAVIST 240 around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	182684	NEW, NON-IONIC X-RAY CONTRAST MATERIALS
Finland	73199
Yugoslavia	61780

ULTRAVIST 240 Market Analysis and Financial Projection

Last updated: February 17, 2026

Market Position and Adoption of ULTRAVIST 240

Ultravist 240 (iopamidol) is an iodinated contrast agent used primarily in diagnostic imaging procedures such as computed tomography (CT) scans. Its market position is shaped by its clinical efficacy, safety profile, and competition from other contrast agents.

Clinical and Regulatory Milestones

Regulatory Status: ULTRAVIST 240 has received approvals from the U.S. Food and Drug Administration (FDA) and multiple global health agencies. Market entry occurred in the late 1980s, with subsequent regulatory updates reflecting safety data and manufacturing improvements.

Indications: Commonly used for vascular, urinary, and soft tissue imaging. Its high iodine content improves radiodensity, vital for detailed imaging.

Market Size and Growth Drivers

Global Market Estimate: The contrast media market was valued at approximately USD 4.7 billion in 2022. Ultravist 240 holds a significant share, estimated at 8-10% within the iodinated contrast agents segment.

Growth Factors:

• Expansion in diagnostic imaging procedures driven by aging populations and rising prevalence of cardiovascular and oncological conditions.
• Increased uptake in emerging markets due to technological advancement and healthcare infrastructure development.
• Continued clinical validation of contrast agents' safety and efficacy.

Constraints and Competition:

• Stringent regulatory requirements and concerns over iodine-related adverse events limit some usage.
• Presence of competitive contrast agents, such as iohexol (Omnipaque) and iopromide (Ultravist 300/370), influences market share.
• Generic competition has increased post-expiration of certain patent protections.

Revenue and Financial Trajectory

Historical Revenue: Exact sales figures are proprietary but approximate global revenues for contrast agents, including Ultravist 240, grew 3-5% annually over the past five years, driven by volume increases offsetting pricing pressures.

Pricing Trends: Pricing has stabilized due to generic competition and commoditization, with unit prices generally declining 1-2% annually.

Forecasting: Projected CAGR from 2023 to 2028 remains in the 2-4% range, considering penetration in emerging markets and device adoption rates.

R&D and Pipeline Positioning

Product Development: Bayer, the manufacturer, is investing in next-generation contrast agents with reduced osmolality and allergy potential. ULTRAVIST 240's formulation is considered mature, with minimal R&D expenditure emphasis.

Pipeline Outlook: No major new formulations of Ultravist 240 are publicly announced; efforts focus on improving safety profiles and expanding indications.

Risks and Market Dynamics

• Regulatory Risks: Continued scrutiny over iodine-based contrast agents' safety.
• Market Competition: Biocompatibility and safety improvements by competitors could erode market share.
• Technological Disruption: Advances in MRI and alternative imaging modalities may reduce dependence on iodinated contrast.

Key Takeaways

• ULTRAVIST 240 occupies a significant, mature position within the iodinated contrast media market.
• Revenue growth is modest, driven by volume increases and geographic expansion.
• Price competition and regulatory scrutiny are primary factors constraining profit margins.
• Investment in next-generation contrast agents is minimal, with focus on optimizing safety.
• Emerging markets offer growth potential but require navigating local regulatory and economic barriers.

FAQs

1. How does ULTRAVIST 240 compare with other iodinated contrast agents in terms of safety?
It has a well-established safety profile with low incidence of adverse reactions, but iodine-related risks persist, especially in patients with thyroid issues or allergies.

2. What are the major competitors to ULTRAVIST 240?
Main competitors include iohexol (Omnipaque), iopromide (Ultravist 300/370), and other high-iodine content contrast agents.

3. How has pricing changed over the past five years?
Pricing has decreased by approximately 1-2% annually due to generic competition and market saturation.

4. What is the potential for ULTRAVIST 240 in emerging markets?
Growing healthcare infrastructure and increasing diagnostic imaging procedures present significant expansion opportunities.

5. What future developments could impact ULTRAVIST 240's market size?
Advances in MRI technology, development of safer contrast media, and shifts in clinical practice guidelines could reduce reliance on iodinated agents.

---

References

1. MarketsandMarkets. Contrast Media Market, 2022.
2. Bayer AG. Ultravist Product Information, 2023.
3. FDA. Approved Drug Products with Therapeutic Equivalence Evaluations, 2022.
4. Global Data Research. Diagnostic Imaging Market Forecast, 2023-2028.